



## ResApp Terminates MOU with RB

**Brisbane, Australia, 23 December 2020** – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, advises that it has terminated the memorandum of understanding (MOU) with global health products manufacturer RB.

ResApp and RB had previously agreed (refer ASX announcement 18 June 2020) to co-develop a smartphone app for consumers that utilises ResApp’s cough-based algorithms. As part of the MOU, the MOU, including the exclusivity could be terminated by either party at no cost if a joint development agreement was not signed within six months.

**CEO and Managing Director Dr Tony Keating said:** *“While we were unable to agree with RB on the scope and timeframe of a joint development program, we maintain a strong belief in the commercial potential of a consumer-facing app utilising our cough-based algorithms. Speed to market is pivotal in developing new technologies and terminating this MOU will allow us to re-accelerate internal development of the product and allow us to engage with a number of other interested parties.”*

###

### About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, a smartphone application which allows consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit [www.resapphealth.com.au](http://www.resapphealth.com.au).

### Contacts

Dr Tony Keating  
CEO and Managing Director  
+61 430 180 659  
[tony@resapphealth.com.au](mailto:tony@resapphealth.com.au)

Mr Brian Leedman  
Vice President, Corporate Affairs  
+61 412 281 780  
[brian@resapphealth.com.au](mailto:brian@resapphealth.com.au)

*This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.*